Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
32
KNSA Quote, Financials, Valuation and Earnings
Last price:
$19.96
Seasonality move
:
-9.83%
Day range:
$20.11 - $20.75
52-week range:
$16.56 - $28.15
Dividend yield:
0%
P/E ratio:
153.73x
P/S ratio:
3.84x
P/B ratio:
3.35x
Volume:
240.1K
Avg. volume:
288.1K
1-year change:
11.02%
Market cap:
$1.5B
Revenue:
$270.3M
EPS (TTM):
-$0.14
Analysts' Opinion
-
Consensus RatingKiniksa Pharmaceuticals International PLC has received a consensus rating of . The company's average rating is a based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Kiniksa Pharmaceuticals International PLC has an estimated upside of 77.78% from its current price of $20.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $20.25.
Fair Value
-
According to the consensus of 0 analysts, Kiniksa Pharmaceuticals International PLC has 77.78% upside to fair value with a price target of -- per share.
KNSA vs. S&P 500
-
Over the past 5 trading days, Kiniksa Pharmaceuticals International PLC has underperformed the S&P 500 by -2.05% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kiniksa Pharmaceuticals International PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kiniksa Pharmaceuticals International PLC has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Kiniksa Pharmaceuticals International PLC reported revenues of $112.2M.
Earnings Growth
-
Kiniksa Pharmaceuticals International PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Kiniksa Pharmaceuticals International PLC reported earnings per share of -$0.18.
Enterprise value:
1.2B
EV / Invested capital:
2.83x
Price / LTM sales:
3.84x
EV / EBIT:
--
EV / Revenue:
3.22x
PEG ratio (5yr expected):
-5.30x
EV / Free cash flow:
111.52x
Price / Operating cash flow:
132.76x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$291M
Return On Assets:
-1.73%
Net Income Margin (TTM):
-2.36%
Return On Equity:
-2.11%
Return On Invested Capital:
-2.11%
Operating Margin:
-8.61%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $177M | $248.7M | $384.1M | $67M | $112.2M | |
| Gross Profit | $140.4M | $195.2M | $291M | $40.6M | $62.8M | |
| Operating Income | -$32.4M | -$19.2M | -$26.2M | -$10.9M | -$9.7M | |
| EBITDA | -$29.9M | -$16.8M | -$24.4M | -$10.3M | -$9.3M | |
| Diluted EPS | $2.00 | -$0.11 | -$0.14 | -$0.20 | -$0.18 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $378.4M | $217.5M | $241.8M | $256.1M | $311.3M | |
| Total Assets | $384.4M | $252.9M | $460M | $483.1M | $555.3M | |
| Current Liabilities | $24.9M | $34.4M | $56.5M | $53.5M | $96M | |
| Total Liabilities | $25.9M | $38.8M | $75.9M | $77.9M | $118.3M | |
| Total Equity | $358.5M | $214M | $384M | $405.1M | $437M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.5M | -$2.6M | $11.2M | $17M | -$2.2M | |
| Cash From Investing | -$15.5M | -$57.3M | -$42.5M | -$12.3M | -$6.3M | |
| Cash From Financing | $2.5M | $2M | $10.8M | $552K | $6.7M | |
| Free Cash Flow | -$1.9M | -$2.6M | $11.1M | $17M | -$2.2M | |
KNSA
Sector
Market Cap
$1.5B
$45.6M
Price % of 52-Week High
71.94%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
0.26%
-0.74%
1-Year Price Total Return
11.02%
-31.35%
Beta (5-Year)
0.268
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$20.32
200-day SMA
Sell
Level
$21.87
Bollinger Bands (100)
Sell
Level
21.85 - 26.21
Chaikin Money Flow
Sell
Level
-2.5M
20-day SMA
Sell
Level
$21.07
Relative Strength Index (RSI14)
Sell
Level
38.01
ADX Line
Sell
Level
1.43
Williams %R
Buy
Level
-80.9756
50-day SMA
Sell
Level
$22.74
MACD (12, 26)
Sell
Level
-0.61
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
29.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.0452)
Buy
CA Score
(Annual)
Level (1.1119)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.855)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Stock Forecast FAQ
In the current month, KNSA has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KNSA average analyst price target in the past 3 months is --.
-
Where Will Kiniksa Pharmaceuticals International PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kiniksa Pharmaceuticals International PLC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Kiniksa Pharmaceuticals International PLC?
Analysts are divided on their view about Kiniksa Pharmaceuticals International PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kiniksa Pharmaceuticals International PLC is a Sell and believe this share price will drop from its current level to --.
-
What Is Kiniksa Pharmaceuticals International PLC's Price Target?
The price target for Kiniksa Pharmaceuticals International PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KNSA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kiniksa Pharmaceuticals International PLC is a . 0 of 0 analysts rate the stock a at this time.
-
How Can I Buy Shares Of KNSA?
You can purchase shares of Kiniksa Pharmaceuticals International PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kiniksa Pharmaceuticals International PLC shares.
-
What Is The Kiniksa Pharmaceuticals International PLC Share Price Today?
Kiniksa Pharmaceuticals International PLC was last trading at $19.96 per share. This represents the most recent stock quote for Kiniksa Pharmaceuticals International PLC. Yesterday, Kiniksa Pharmaceuticals International PLC closed at $20.25 per share.
-
How To Buy Kiniksa Pharmaceuticals International PLC Stock Online?
In order to purchase Kiniksa Pharmaceuticals International PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.46% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.62% over the past day.
